A new study by researchers at Yale Cancer Center shows inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing. The discovery is an early step in finding new therapeutics for triple-negative breast cancer (TNBC), one of the most difficult disease sub-types to treat. The findings are published online February 4 in the journal Science Translational Medicine.
To learn more, go to: New path to treat advanced triple-negative breast cancer — ScienceDaily
(Reprinted from Science Daily, February 4, 2022)